Mallinckrodt Announces New England Journal of Medicine Publication of Results from its Phase 3 CONFIRM Study of Terlipressin in Patients with Hepatorenal Syndrome Type 1 (HRS-1)
- Thursday, March 4, 2021, 7:04
- Finance
- Add a comment
DUBLIN, March 4, 2021 /PRNewswire/ — Mallinckrodt plc, a global biopharmaceutical company, today announced publication of results from its pivotal Phase 3 CONFIRM study to assess the efficacy and safety of its investigational agent terlipressin in adults with hepatorenal syndrome type 1…
About the Author
adminasapcorp has written 41302 stories on this site.